Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003

Solid Biosciences announced a widely anticipated update on their INSPIRE DUCHENNE Phase 1/2 clinical trial of SGT-003, their investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy.

• 15 participants have received SGT-003 so far across sites in the U.S., Canada, Italy, and the UK.
• No serious treatment-related adverse effects have been reported, and early safety results remain positive.
• The company plans to dose a minimum of 20 participants this year and expects to meet with the U.S. FDA to discuss regulatory pathways for SGT-003 later this year.

What this means for families:
While this therapy is still in clinical testing, the results are promising and highlight progress towards more gene therapy treatment options for Duchenne. The Company expects to initiate a separate randomized, double-blind, placebo-controlled trial evaluating SGT-003 outside of the United States in the fourth quarter of 2025, with the aim of supporting potential global regulatory authorizations.

See the press release and the letter to the community.